Mirna Therapeutics Inc. (NASDAQ:MIRN) was downgraded by analysts at Oppenheimer Holdings Inc. from an “outperform” rating to a “market perform” rating in a note issued to investors on Wednesday.
Several other brokerages have also issued reports on MIRN. Zacks Investment Research upgraded Mirna Therapeutics from a “hold” rating to a “buy” rating and set a $5.00 price target for the company in a report on Thursday, July 14th. Citigroup Inc. lowered Mirna Therapeutics from a “buy” rating to a “neutral” rating and reduced their price target for the company from $7.00 to $4.50 in a report on Tuesday, August 16th. Leerink Swann lowered Mirna Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $10.00 to $4.00 in a report on Monday, August 15th. HC Wainwright assumed coverage on Mirna Therapeutics in a report on Monday, September 12th. They set a “buy” rating and a $6.00 price target for the company. Finally, Cantor Fitzgerald lowered Mirna Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Mirna Therapeutics currently has a consensus rating of “Hold” and an average price target of $6.96.
Mirna Therapeutics (NASDAQ:MIRN) opened at 1.96 on Wednesday. Mirna Therapeutics has a 1-year low of $1.82 and a 1-year high of $11.01. The stock’s market capitalization is $40.84 million. The stock’s 50 day moving average price is $3.05 and its 200 day moving average price is $4.08.
About Mirna Therapeutics
Mirna Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response.
Receive News & Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.